Helus Pharma (HELP) Canaccord Genuity's 46th Annual Growth Conference summary

Key leadership and strategic vision

• New CEO Michael Halstead brings over 25 years of industry experience, including leading a CNS company through growth and acquisition.

• Leadership transition is marked by strong alignment with the board and a shared vision to transform mental health treatment.

• CEO emphasizes the importance of execution, team competence, and passion for mental health impact.

• Strategic focus is on building a fully integrated commercial company and expanding clinical programs.

Clinical pipeline and trial progress

• Lead candidate HLP003, a deuterated psilocin, is in phase III for adjunctive major depressive disorder, with top-line data expected in Q4.

• Phase II results for HLP003 showed 13–14 point MADRS improvement after one dose, with strong durability and safety profile.

• Phase III design closely follows successful phase II, incorporating a two-dose induction for enhanced durability.

• Enrollment for phase III is complete, and clinical trial execution is closely managed at the site level.

Product differentiation and intellectual property

• HLP003 is differentiated by its deuteration, enabling composition of matter patents and improved pharmacokinetics.

• Broad patent portfolio covers multiple programs, including HLP004 and HLP005, supporting long-term sustainability.

• Deuteration offers benefits such as lower drug load, stability, and reduced PK/PD variance.